K

BVF Partners logo

BVF Partners

Crunchbase
Pitchbook
Crunchbase

Deals on record

9

Common Fundraising Type

Series A

Numab Therapeutics logo
Numab Therapeutics

Biotech • Immunotherapies

RTW Investments logo
Novo Holdings logo
Octagon Capital Advisors logo
HBM Healthcare Investment logo

Numab Therapeutics is a biotech company that develops multi-specific antibody-based immunotherapies for inflammation and cancer.

Series C
$55M
01/10/2025
Article
Ambrosia Biosciences logo
Ambrosia Biosciences

Drug discovery • Small molecule therapies

Merck logo
BVF Partners logo
Boulder Ventures logo

Ambrosia Biosciences develops orally delivered, small molecule-based therapies for obesity and metabolic disorders.

Series A
$25M
12/11/2024
Article
Alpha-9 Oncology logo
Alpha-9 Oncology

Radiopharmaceuticals • Clinical-stage

Ascenta Capital logo
Lightspeed Venture Partners logo
Samsara BioCapital logo
RA Capital Management logo

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Series C
$175M
10/23/2024
Article
Bambusa Therapeutics logo
Bambusa Therapeutics

Biotechnology • Bispecific antibodies

Bambusa Therapeutics Inc. develops bispecific antibodies for treating immunological and inflammatory disorders.

Seed
$15M
09/09/2024
Article
Ambrosia Biosciences logo
Ambrosia Biosciences

Drug discovery • Small molecule therapies

Boulder Ventures logo
BVF Partners logo

Ambrosia Biosciences develops orally delivered, small molecule-based therapies for obesity and metabolic disorders.

Series A
$16M
08/21/2024
Article
Lassen Therapeutics logo
Lassen Therapeutics

Clinical-stage biotech • IL-11 receptor

Longitude Capital logo
Longwood Capital logo
Frazier Life Sciences logo
Catalio Capital Management logo

Lassen Therapeutics is a clinical-stage biotech company developing novel treatments for fibro-inflammatory diseases and cancer, focusing on therapies targeting the IL-11 and IL-18 pathways.

Series B
$85M
12/19/2023
Article
Aro Biotherapeutics logo
Aro Biotherapeutics

Biotechnology • Genetic Medicines

Cowen Healthcare Investments logo
Johnson & Johnson Innovation logo
Northpond Ventures logo
Healthcap logo

Aro Biotherapeutics is a clinical stage biotech company specializing in the development of tissue-targeted genetic medicines, including a potential treatment for Pompe Disease and new therapies for autoimmune disorders, using their proprietary Centyrin-siRNA platform.

Series B
$41.5M
11/28/2023
Article
Forward Therapeutics logo
Forward Therapeutics

Biotechnology • Immune Therapies

RA Capital Management logo
OrbiMed logo
BVF Partners logo

Forward Therapeutics is a company focused on advancing the development of next-generation small molecule immune therapies.

Series A
$50M
11/08/2023
Article
Nimbus Therapeutics logo
Nimbus Therapeutics

Computational Drug Discovery • Immunology

SR One logo
GV logo
Atlas Venture logo
SV Health Investors logo

Nimbus Therapeutics is a clinical-stage company that uses computational chemistry and structure-based drug design to develop novel therapies for immunology, cancer, and metabolic diseases.

Equity
$210M
09/06/2023
Article